OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
John B. Buse, Deborah J. Wexler, Απόστολος Τσάπας, et al.
Diabetes Care (2019) Vol. 43, Iss. 2, pp. 487-493
Open Access | Times Cited: 1050
John B. Buse, Deborah J. Wexler, Απόστολος Τσάπας, et al.
Diabetes Care (2019) Vol. 43, Iss. 2, pp. 487-493
Open Access | Times Cited: 1050
Showing 26-50 of 1050 citing articles:
CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries
Ofri Mosenzon, Abdullah Alguwaihes, Jose Luis Arenas Leon, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 175
Ofri Mosenzon, Abdullah Alguwaihes, Jose Luis Arenas Leon, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 175
Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England
Kamlesh Khunti, Peter Knighton, Francesco Zaccardi, et al.
The Lancet Diabetes & Endocrinology (2021) Vol. 9, Iss. 5, pp. 293-303
Open Access | Times Cited: 172
Kamlesh Khunti, Peter Knighton, Francesco Zaccardi, et al.
The Lancet Diabetes & Endocrinology (2021) Vol. 9, Iss. 5, pp. 293-303
Open Access | Times Cited: 172
The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk
Cyrielle Caussy, Adrien Aubin, Rohit Loomba
Current Diabetes Reports (2021) Vol. 21, Iss. 5
Open Access | Times Cited: 152
Cyrielle Caussy, Adrien Aubin, Rohit Loomba
Current Diabetes Reports (2021) Vol. 21, Iss. 5
Open Access | Times Cited: 152
Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)
Rong Li, Junyan Zou, Wei Ran, et al.
Frontiers in Endocrinology (2023) Vol. 13
Open Access | Times Cited: 149
Rong Li, Junyan Zou, Wei Ran, et al.
Frontiers in Endocrinology (2023) Vol. 13
Open Access | Times Cited: 149
Diabetes Management in Chronic Kidney Disease: Synopsis of the 2020 KDIGO Clinical Practice Guideline
Sankar D. Navaneethan, Sophia Zoungas, Maria Luiza Caramori, et al.
Annals of Internal Medicine (2020) Vol. 174, Iss. 3, pp. 385-394
Open Access | Times Cited: 147
Sankar D. Navaneethan, Sophia Zoungas, Maria Luiza Caramori, et al.
Annals of Internal Medicine (2020) Vol. 174, Iss. 3, pp. 385-394
Open Access | Times Cited: 147
Pathophysiology, phenotypes and management of type 2 diabetes mellitus in Indian and Chinese populations
Calvin Ke, K.M. Venkat Narayan, Juliana C.N. Chan, et al.
Nature Reviews Endocrinology (2022) Vol. 18, Iss. 7, pp. 413-432
Open Access | Times Cited: 147
Calvin Ke, K.M. Venkat Narayan, Juliana C.N. Chan, et al.
Nature Reviews Endocrinology (2022) Vol. 18, Iss. 7, pp. 413-432
Open Access | Times Cited: 147
Glycemia Reduction in Type 2 Diabetes — Glycemic Outcomes
David M. Nathan, John M. Lachin, Ashok Balasubramanyam, et al.
New England Journal of Medicine (2022) Vol. 387, Iss. 12, pp. 1063-1074
Open Access | Times Cited: 145
David M. Nathan, John M. Lachin, Ashok Balasubramanyam, et al.
New England Journal of Medicine (2022) Vol. 387, Iss. 12, pp. 1063-1074
Open Access | Times Cited: 145
Comparative efficacy of glucose‐lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta‐analysis
Απόστολος Τσάπας, Thomas Karagiannis, Panagiota Kakotrichi, et al.
Diabetes Obesity and Metabolism (2021) Vol. 23, Iss. 9, pp. 2116-2124
Closed Access | Times Cited: 127
Απόστολος Τσάπας, Thomas Karagiannis, Panagiota Kakotrichi, et al.
Diabetes Obesity and Metabolism (2021) Vol. 23, Iss. 9, pp. 2116-2124
Closed Access | Times Cited: 127
Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists
Agata Winiarska, Monika Knysak, Katarzyna Nabrdalik, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 19, pp. 10822-10822
Open Access | Times Cited: 124
Agata Winiarska, Monika Knysak, Katarzyna Nabrdalik, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 19, pp. 10822-10822
Open Access | Times Cited: 124
Should metformin remain the first-line therapy for treatment of type 2 diabetes?
Chelsea Baker, Cimmaron Retzik-Stahr, Vatsala Singh, et al.
Therapeutic Advances in Endocrinology and Metabolism (2021) Vol. 12
Open Access | Times Cited: 113
Chelsea Baker, Cimmaron Retzik-Stahr, Vatsala Singh, et al.
Therapeutic Advances in Endocrinology and Metabolism (2021) Vol. 12
Open Access | Times Cited: 113
Glycemia Reduction in Type 2 Diabetes — Microvascular and Cardiovascular Outcomes
David M. Nathan, John M. Lachin, Ionut Bebu, et al.
New England Journal of Medicine (2022) Vol. 387, Iss. 12, pp. 1075-1088
Open Access | Times Cited: 102
David M. Nathan, John M. Lachin, Ionut Bebu, et al.
New England Journal of Medicine (2022) Vol. 387, Iss. 12, pp. 1075-1088
Open Access | Times Cited: 102
Pharmacotherapy of type 2 diabetes: An update and future directions
Antea DeMarsilis, Niyoti Reddy, Chrysoula Boutari, et al.
Metabolism (2022) Vol. 137, pp. 155332-155332
Closed Access | Times Cited: 95
Antea DeMarsilis, Niyoti Reddy, Chrysoula Boutari, et al.
Metabolism (2022) Vol. 137, pp. 155332-155332
Closed Access | Times Cited: 95
Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes
Alison K. Wright, Matthew Carr, Evangelos Kontopantelis, et al.
Diabetes Care (2022) Vol. 45, Iss. 4, pp. 909-918
Open Access | Times Cited: 94
Alison K. Wright, Matthew Carr, Evangelos Kontopantelis, et al.
Diabetes Care (2022) Vol. 45, Iss. 4, pp. 909-918
Open Access | Times Cited: 94
Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes
Aditi R. Saxena, Juan P. Frías, Lisa Brown, et al.
JAMA Network Open (2023) Vol. 6, Iss. 5, pp. e2314493-e2314493
Open Access | Times Cited: 81
Aditi R. Saxena, Juan P. Frías, Lisa Brown, et al.
JAMA Network Open (2023) Vol. 6, Iss. 5, pp. e2314493-e2314493
Open Access | Times Cited: 81
Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system
Yamin Shu, Xu‐Cheng He, Pan Wu, et al.
Frontiers in Public Health (2022) Vol. 10
Open Access | Times Cited: 76
Yamin Shu, Xu‐Cheng He, Pan Wu, et al.
Frontiers in Public Health (2022) Vol. 10
Open Access | Times Cited: 76
Advanced Glycation End Products and Their Effect on Vascular Complications in Type 2 Diabetes Mellitus
Jeongmin Lee, Jae‐Seung Yun, Seung‐Hyun Ko
Nutrients (2022) Vol. 14, Iss. 15, pp. 3086-3086
Open Access | Times Cited: 73
Jeongmin Lee, Jae‐Seung Yun, Seung‐Hyun Ko
Nutrients (2022) Vol. 14, Iss. 15, pp. 3086-3086
Open Access | Times Cited: 73
C‐peptide determination in the diagnosis of type of diabetes and its management: A clinical perspective
Ernesto Maddaloni, Geremia B. Bolli, Brian M. Frier, et al.
Diabetes Obesity and Metabolism (2022) Vol. 24, Iss. 10, pp. 1912-1926
Open Access | Times Cited: 72
Ernesto Maddaloni, Geremia B. Bolli, Brian M. Frier, et al.
Diabetes Obesity and Metabolism (2022) Vol. 24, Iss. 10, pp. 1912-1926
Open Access | Times Cited: 72
Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial
Vanita R. Aroda, Jens Aberle, Lars Bardtrum, et al.
The Lancet (2023) Vol. 402, Iss. 10403, pp. 693-704
Open Access | Times Cited: 61
Vanita R. Aroda, Jens Aberle, Lars Bardtrum, et al.
The Lancet (2023) Vol. 402, Iss. 10403, pp. 693-704
Open Access | Times Cited: 61
Comparing Effectiveness and Safety of SGLT2 Inhibitors vs DPP-4 Inhibitors in Patients With Type 2 Diabetes and Varying Baseline HbA1c Levels
Elvira D’Andrea, Deborah J. Wexler, Seoyoung C. Kim, et al.
JAMA Internal Medicine (2023) Vol. 183, Iss. 3, pp. 242-242
Open Access | Times Cited: 54
Elvira D’Andrea, Deborah J. Wexler, Seoyoung C. Kim, et al.
JAMA Internal Medicine (2023) Vol. 183, Iss. 3, pp. 242-242
Open Access | Times Cited: 54
Epidemiology of Diabetes and Atherosclerotic Cardiovascular Disease Among Asian American Adults: Implications, Management, and Future Directions: A Scientific Statement From the American Heart Association
Tak Kwan, Sally S. Wong, Yuling Hong, et al.
Circulation (2023) Vol. 148, Iss. 1, pp. 74-94
Closed Access | Times Cited: 53
Tak Kwan, Sally S. Wong, Yuling Hong, et al.
Circulation (2023) Vol. 148, Iss. 1, pp. 74-94
Closed Access | Times Cited: 53
Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study
Nikita Simms-Williams, Nir Treves, Hui Yin, et al.
BMJ (2024), pp. e078242-e078242
Open Access | Times Cited: 33
Nikita Simms-Williams, Nir Treves, Hui Yin, et al.
BMJ (2024), pp. e078242-e078242
Open Access | Times Cited: 33
Glucagon-Like Peptide-1: New Regulator in Lipid Metabolism
Tong Bu, Ziyan Sun, Yi Pan, et al.
Diabetes & Metabolism Journal (2024) Vol. 48, Iss. 3, pp. 354-372
Open Access | Times Cited: 22
Tong Bu, Ziyan Sun, Yi Pan, et al.
Diabetes & Metabolism Journal (2024) Vol. 48, Iss. 3, pp. 354-372
Open Access | Times Cited: 22
Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence
Radica Z. Alicic, Emily J. Cox, Joshua J. Neumiller, et al.
Nature Reviews Nephrology (2020) Vol. 17, Iss. 4, pp. 227-244
Closed Access | Times Cited: 132
Radica Z. Alicic, Emily J. Cox, Joshua J. Neumiller, et al.
Nature Reviews Nephrology (2020) Vol. 17, Iss. 4, pp. 227-244
Closed Access | Times Cited: 132
Guideline recommendations and the positioning of newer drugs in type 2 diabetes care
Nikolaus Marx, Melanie J. Davies, Peter J. Grant, et al.
The Lancet Diabetes & Endocrinology (2020) Vol. 9, Iss. 1, pp. 46-52
Open Access | Times Cited: 131
Nikolaus Marx, Melanie J. Davies, Peter J. Grant, et al.
The Lancet Diabetes & Endocrinology (2020) Vol. 9, Iss. 1, pp. 46-52
Open Access | Times Cited: 131
The Current and Potential Therapeutic Use of Metformin—The Good Old Drug
Józef Drzewoski, M Hanefeld
Pharmaceuticals (2021) Vol. 14, Iss. 2, pp. 122-122
Open Access | Times Cited: 101
Józef Drzewoski, M Hanefeld
Pharmaceuticals (2021) Vol. 14, Iss. 2, pp. 122-122
Open Access | Times Cited: 101
